Stage IIB triple-negative metaplastic breast cancer with early metastatic recurrence: durable response to pembrolizumab-based therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Triple-negative metaplastic breast cancer with PD-L1 CPS 83.2, BRCA1/2 negative

Metastatic Site: lung, sternum

As of May 2026, she had more than 30 months of disease control after pembrolizumab-based therapy for early recurrent metastatic metaplastic breast cancer, with only mild residual sternal uptake and no disease progression.

PubMed CentralRead more →

Stage ypT1aN0 triple-negative breast cancer with familial BRCA1 and OBSCN deletions

Patient Info: Anonymized, Female, Under 40

Biomarkers: Triple-negative breast cancer; HER2 1+/negative; Ki-67 20%+. Familial testing showed BRCA1 and OBSCN deletions.

She underwent modified radical mastectomy with sentinel lymph node dissection and continued postoperative follow-up, with the main clinical emphasis on familial BRCA1/OBSCN genetic susceptibility.

PubMed CentralRead more →

Three separate primary cancers: lung squamous carcinoma, gastric adenocarcinoma, and hepatocellular carcinoma

Patient Info: Anonymized, Male, 60s

Biomarkers: Multiple primaries: lung squamous markers CK5/6 and P40; gastric cancer HER2 negative; liver cancer markers hepatocyte/GPC3/HSP70/CD34.

As of May 2026, all 3 primary cancers were controlled: lung cancer had no recurrence after surgery, gastric cancer remained in sustained remission on sintilimab maintenance, and hepatocellular carcinoma was controlled after ablation; ECOG performance status was 1.

PubMed CentralRead more →

Triple-Negative Breast Cancer: Jes's Survivor Story

Patient Info: Jes, Female

Biomarkers: ER-negative; PR-negative; HER2-negative

No evidence of disease after chemotherapy/immunotherapy and bilateral mastectomy; no positive lymph nodes were found, chemotherapy cleared the cancer, and radiation was not needed, though she continued to experience long-term treatment effects.

The Patient StoryRead more →

Triple-Negative Breast Cancer: Marina's Survivor Story

Patient Info: Marina, Female, Under 40

Biomarkers: BRCA1 mutation; triple-negative breast cancer

Triple-negative breast cancer survivor with a BRCA1 mutation who completed treatment after an initial diagnosis and a second diagnosis at the 5-year mark; no formal stage or metastatic disease was stated in the available source text.

The Patient StoryRead more →

Triple-Negative Breast Cancer: Jacqueline's Patient Story

Patient Info: Jacqueline Bennett, Female, Under 40

Biomarkers: Initial ER-negative, PR-negative, HER2-negative; later HER2-positive

Jacqueline completed treatment for initial Stage IA triple-negative breast cancer during pregnancy and later developed a HER2-positive, hormone receptor-negative breast cancer. After 3 of 6 current treatments, the tumor was no longer visible on ultrasound or MRI, with targeted therapy and double mastectomy still planned.

The Patient StoryRead more →

Triple-negative breast cancer diagnosed during pregnancy: remission

Patient Info: Anonymized, Female, Under 40

Biomarkers: ER-negative; PR-negative; HER2-negative

The patient remains in remission 30 months after surgery. Immune-related brachial plexopathy after treatment improved after steroids, IVIG, and plasmapheresis, with electrophysiologic resolution and near-complete strength and sensory recovery.

PubMed CentralRead more →

Non-metastatic metaplastic triple-negative breast cancer with residual disease after chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Metaplastic triple-negative breast cancer; HER2 0

The patient had an initial partial response to neoadjuvant chemotherapy but then progressed before surgery. Modified radical mastectomy found substantial residual metaplastic carcinoma with 0/21 nodes involved, followed by adjuvant radiotherapy and metronomic capecitabine.

PubMed CentralRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: Janet's Patient Story

Patient Info: Janet Ayala, Female, Under 40 | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive; ATM mutation

After complete pathologic response and completion of HER2-targeted infusions, Janet remained in survivorship-focused ongoing care with estrogen suppression and additional endocrine/targeted therapy planning to reduce recurrence risk.

City of HopeRead more →

Stage IIIB triple-negative metaplastic breast cancer: urgent mastectomy and reconstruction after rapid progression on neoadjuvant therapy

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative; nuclear grade 3

At 18-month follow-up, she was disease-free after urgent mastectomy, axillary dissection, flap/skin-graft reconstruction, resumed chemotherapy, and radiation for rapidly progressive triple-negative metaplastic breast cancer.

PubMed CentralRead more →

Stage 4 breast cancer: 4 years and counting

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Initial tumor: hormone receptor-positive; HER2 1+. Metastatic recurrence: triple-negative breast cancer.

Metastatic Site: liver, bone, lung, supraclavicular lymph nodes,…

After response of choroidal metastases to eye radiation plus sacituzumab govitecan, disease progressed in February 2023 with cerebellar and pituitary brain lesions; she developed obstructive hydrocephalus, entered hospice in May 2023, and died in June 2023.

PubMed CentralRead more →

Metastatic triple-negative breast cancer with sacituzumab-govitecan pneumonitis and progression

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

Metastatic Site: lung

Sacituzumab-govitecan pneumonitis improved with corticosteroids and half-dose rechallenge did not reproduce pneumonitis, but follow-up CT showed one new pulmonary metastasis and enlargement of previous lung metastases; PFS on sacituzumab govitecan was 5.37 months.

PubMed CentralRead more →

Stage II Triple-Negative Breast Cancer: Chase's Survivor Story

Patient Info: Chase, Female, Under 40 | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative

As of January 2026, Chase had shown no evidence of cancer for nearly 5 years after Stage IIB triple-negative breast cancer treatment and had completed 3 investigational vaccine injections without significant side effects.

Cleveland ClinicRead more →

Stage IV triple-negative invasive lobular breast cancer with HER2 mutations: complete metabolic response to trastuzumab deruxtecan

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Triple-negative invasive lobular breast cancer with HER2-low/dubious staining and HER2 FISH-negative; somatic ERBB2/HER2 and mutations.

Metastatic Site: iliac bone lesions / bone metastases

As of January 2026, metastatic triple-negative invasive lobular breast cancer with HER2 mutations had a sustained complete metabolic response to trastuzumab deruxtecan for 20 months, with dose reduction for neutropenia and no pulmonary toxicity.

PubMed CentralRead more →

Stage II HR-Positive Breast Cancer: Sian's Survivor Story

Patient Info: Sian Bevans, Female, 50s | Stage II

Biomarkers: Triple-positive

Sian was 11 years past diagnosis, completed 10 years of maintenance medication in May 2025, and reported feeling more like herself; no recurrence was described.

Cleveland ClinicRead more →

Stage 3 triple-negative breast cancer complicated by immunotherapy endocrine toxicity

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: ER-negative; PgR-negative/PR-negative; HER2 0; Ki-67 70%; triple-negative breast cancer

After neoadjuvant therapy complicated by immune-related hypothyroidism, adrenal insufficiency, and suspected hypophysitis, surgery showed residual ypT1c ypN0 triple-negative disease. Pembrolizumab was stopped, adjuvant capecitabine was completed in June 2025, and endocrine replacement/follow-up continued.

PubMed CentralRead more →

Triple-negative breast cancer with occult metastasis in parathyroid and ectopic thyroid adenomas: complete remission after chemotherapy

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Triple-negative breast cancer. Metastatic deposits were CK7 positive and negative for ER, HER2

Metastatic Site: parathyroid adenoma; ectopic thyroid adenoma /…

As of December 2025, she remained in complete remission 1 year after systemic chemotherapy for triple-negative breast cancer with occult metastatic deposits in parathyroid and ectopic thyroid adenomas.

PubMed CentralRead more →

Stage IV Triple-Negative Breast Cancer: Chelsey's Patient Story

Patient Info: Chelsey Pickthorn, Female | Stage IV

Biomarkers: Triple-negative breast cancer

As of December 2025, Chelsey was described as a patient advocate living with Stage IV triple-negative breast cancer, with the conversation focused on LGBTQ+ sexuality, relationships, disclosure, caregiving, body image, and inclusive cancer care.

Stage I AR-positive triple-negative invasive apocrine breast carcinoma: disease-free after surgery, radiotherapy and chemotherapy

Patient Info: Anonymized, Female, 50s | Stage I

Biomarkers: Triple-negative apocrine breast carcinoma with androgen receptor 90%

At 1-year follow-up, she remained disease-free with no clinical or radiologic evidence of recurrence.

PubMed CentralRead more →

Triple-negative breast cancer with pathologic complete response after neoadjuvant chemoimmunotherapy complicated by immune toxicity

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative

Left mastectomy on November 17 confirmed pathologic complete response, and 5-month follow-up showed no residual hepatic, dermatological, metabolic, or neurological sequelae from the treatment-related complications.

PubMed CentralRead more →

HER2-Positive Breast Cancer: Janella's Survivor Story

Patient Info: Janella Bustamante, Female, 40s

Biomarkers: Triple-positive: estrogen-, progesterone- and HER2-fueled breast cancer

As of October 2025, Janella had completed lumpectomy, chemotherapy, radiation and HER2-targeted biological therapy for triple-positive breast cancer and was on follow-up every 3 months; the source describes life after cancer but does not explicitly state NED/cancer-free.

Cleveland ClinicRead more →

Stage IV HER2-Positive Breast Cancer: Paul's Patient Story

Patient Info: Paul Forgette, Male, 60s | Stage IV

Biomarkers: HER2-positive; triple-positive breast cancer; CHEK2 mutation

Metastatic Site: Bones; lymph nodes

By October 2025, 9 months after starting Enhertu, Paul’s Stage IV HER2-positive male breast cancer was described as dormant, not cured, with continued City of Hope care and integrative support.

City of HopeRead more →

Stage IV Triple-Negative Breast Cancer: Nicole's Patient Story

Patient Info: Nicole, Female, 40s | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

Metastatic Site: liver

Nicole remained in active treatment for liver-metastatic triple-negative breast cancer, with meaningful response after switching to an antibody-drug conjugate and then undergoing mastectomy.

The Patient StoryRead more →

PT2N0M0 breast malignant adenomyoepithelioma: disease-free after excision and radiation

Patient Info: Anonymized, Female, 50s

Biomarkers: p63-positive; E-cadherin-positive; CK7-negative on pathology re-review; ER-negative; PR-negative; HER2/neu-negative; sentinel lymph node negative, triple negative

Alive with no evidence of disease after 78 months of follow-up following wide local excision and adjuvant breast radiation.

PubMed CentralRead more →